Kazia Therapeutics Limited (KZIA)

Etorro trading 970x250
Kazia Therapeutics Limited (KZIA) Logo

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia’s investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia. Address: Three International Towers, Sydney, NSW, Australia, 2000

Kazia Therapeutics Limited News and around…

Latest news about Kazia Therapeutics Limited (KZIA) common stock and company :

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
07 Jan, 2022 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022. The company has been invited to participate via a 'fireside chat' with a senior equity research analyst at the bank.

Independent Non-Executive Director Steven Coffey Just Bought 12% More Shares In Kazia Therapeutics Limited (ASX:KZA)
24 Dec, 2021 Yahoo! Finance

Even if it's not a huge purchase, we think it was good to see that Steven Coffey, the Independent Non-Executive...

KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER
13 Dec, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer.

A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High
13 Dec, 2021 FinancialContent

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the ...

60 Biggest Movers From Yesterday
07 Dec, 2021 FinancialContent

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the ...

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
04 Dec, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.

Kazia Therapeutics Becomes Oversold (KZIA)
03 Dec, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients
03 Dec, 2021 FinancialContent

Australia-basedKazia Therapeutics Limited(NASDAQ: KZIA) announcedfinal data from a Phase 2 studyof paxalisib as ...

GBM AGILE Opens to Paxalisib in Canada
29 Nov, 2021 Yahoo! Finance

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug.

Multiple insiders bought Kazia Therapeutics Limited (ASX:KZA) stock earlier this year, a positive sign for shareholders
29 Nov, 2021 Yahoo! Finance

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
15 Nov, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer.

A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
15 Nov, 2021 FinancialContent

Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are ...

PNOC Study in Childhood Brain Cancer Enrols First Patient
11 Nov, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study.

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
04 Nov, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:REI) was changed from Neutral to Buy. For the second ...

Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
14 Oct, 2021 FinancialContent
What Kind Of Investors Own Most Of Kazia Therapeutics Limited (ASX:KZA)?
13 Oct, 2021 Yahoo! Finance

If you want to know who really controls Kazia Therapeutics Limited ( ASX:KZA ), then you'll have to look at the makeup...

Kazia Therapeutics to Present at LD Micro Main Event
06 Oct, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 October 2021.

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
10 Sep, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021.

Investing in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 241% gain
07 Sep, 2021 Yahoo! Finance

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Proactive news headlines including Great Boulder Resources, Pan Asia Metals, Chimeric Therapeutics and archTIS
02 Sep, 2021 FinancialContent
When Will Kazia Therapeutics Limited (ASX:KZA) Breakeven?
02 Aug, 2021 Yahoo! Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Kazia Therapeutics...

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
21 Jul, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
30 Jun, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.

How Many Kazia Therapeutics Limited (ASX:KZA) Shares Did Insiders Buy, In The Last Year?
16 Jun, 2021 Yahoo! Finance

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
15 Jun, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II clinical study investigating the use of Kazia's investigational new drug, paxalisib, in combination with ketogenesis, for glioblastoma.

Proactive news headlines including Buru Energy, Meteoric Resources, MGC Pharmaceuticals and Vango Mining
15 Jun, 2021 FinancialContent
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
07 Jun, 2021 Yahoo! Finance

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study.

Proactive news headlines including Okapi Resources, Global Energy Ventures, Kazia Therapeutics and QMines
07 Jun, 2021 FinancialContent
Proactive news headlines including Chase Mining Corporation, Red River Resources, Aurumin and Kazia Therapeutics
26 Apr, 2021 FinancialContent

Kazia Therapeutics Limited (KZIA) is a NASDAQ Common Stock listed in , ,

970x250